Histone	B:C1512474
deacetylase	I:C1512474
inhibitors	I:C1512474
regulate	O
P	B:C0242643
-	I:C0242643
gp	I:C0242643
expression	B:C1171362
in	O
colorectal	B:C1527249
cancer	I:C1527249
via	O
transcriptional	B:C0162493
activation	I:C0162493
and	O
mRNA	B:C1327287
stabilization	I:C1327287
.	O

Histone	B:C1512474
deacetylase	I:C1512474
inhibitors	I:C1512474
(	O
Histone	B:C1512474
deacetylase	I:C1512474
inhibitors	I:C1512474
)	O
are	O
emerging	O
as	O
a	O
novel	O
class	B:C0456387
of	O
anti-tumor	B:C0003392
drugs	I:C0003392
.	O

But	O
the	O
effect	O
of	O
Histone	B:C1512474
deacetylase	I:C1512474
inhibitors	I:C1512474
in	O
tumors	B:C0027651
treatment	B:C0087111
has	O
been	O
disappointing	O
,	O
which	O
mainly	O
due	O
to	O
the	O
acquisition	O
of	O
resistance	B:C0013203
to	O
Histone	B:C1512474
deacetylase	I:C1512474
inhibitors	I:C1512474
.	O

In	O
this	O
study	B:C2603343
,	O
it	O
was	O
found	O
that	O
Histone	B:C1512474
deacetylase	I:C1512474
inhibitors	I:C1512474
SAHA	B:C0672708
and	O
TSA	B:C0077063
increased	O
P	B:C0242643
-	I:C0242643
gp	I:C0242643
expression	B:C1171362
in	O
CRC	B:C0334227
cells	I:C0334227
,	O
which	O
has	O
been	O
well	O
known	O
to	O
contribute	O
to	O
drug	B:C0282588
resistant	I:C0282588
.	O

We	O
showed	O
that	O
Histone	B:C1512474
deacetylase	I:C1512474
inhibitors	I:C1512474
enhanced	O
transcriptional	B:C0040649
activity	I:C0040649
of	O
P	B:C0242643
-	I:C0242643
gp	I:C0242643
protein	B:C0376622
encoding	I:C0376622
gene	I:C0376622
ABCB1	I:C0376622
.	O

Histone	B:C1512474
deacetylase	I:C1512474
inhibitors	I:C1512474
treatment	B:C0087111
also	O
increased	O
the	O
protein	B:C0033684
and	O
mRNA	B:C0017262
expression	I:C0017262
of	O
STAT3	B:C0253050
,	O
but	O
not	O
PXR	B:C1744349
,	O
CAR	B:C0663285
,	O
Foxo3a	B:C1333633
or	O
Î²-	B:C0105770
catenin	I:C0105770
,	O
which	O
are	O
known	O
to	O
be	O
involved	O
in	O
ABCB	B:C1158770
transcription	I:C1158770
regulation	I:C1158770
.	O

Interestingly	O
,	O
knockdown	B:C2350567
of	O
STAT3	B:C0253050
significantly	O
attenuated	O
Histone	B:C1512474
deacetylase	I:C1512474
inhibitors	I:C1512474
-	O
induced	O
P	B:C0242643
-	I:C0242643
gp	I:C0242643
up	B:C0041904
-	I:C0041904
regulation	I:C0041904
in	O
colorectal	B:C0334227
cancer	I:C0334227
cells	I:C0334227
,	O
suggesting	O
that	O
STAT3	B:C0253050
plays	O
a	O
crucial	O
role	O
in	O
Histone	B:C1512474
deacetylase	I:C1512474
inhibitors	I:C1512474
-	O
up	B:C0041904
-	I:C0041904
regulated	I:C0041904
P	B:C0242643
-	I:C0242643
gp.	I:C0242643

Furthermore	O
,	O
this	O
study	B:C2603343
revealed	O
for	O
the	O
first	O
time	O
that	O
Histone	B:C1512474
deacetylase	I:C1512474
inhibitors	I:C1512474
enhanced	O
the	O
stability	B:C1257825
of	I:C1257825
ABCB1	I:C1257825
at	O
post	B:C0035684
-	I:C0035684
transcriptional	I:C0035684
level	I:C0035684
.	O

Taken	O
together	O
,	O
these	O
results	O
proved	O
that	O
Histone	B:C1512474
deacetylase	I:C1512474
inhibitors	I:C1512474
induced	O
P	B:C0242643
-	I:C0242643
gp	I:C0242643
expression	B:C1171362
by	O
two	O
distinct	O
ways	O
,	O
transcriptional	B:C0162493
activation	I:C0162493
and	O
mRNA	B:C1327287
stabilization	I:C1327287
.	O

Our	O
results	O
suggested	O
that	O
more	O
attention	O
should	O
be	O
paid	O
to	O
the	O
cancer	B:C0920425
treatment	I:C0920425
using	O
Histone	B:C1512474
deacetylase	I:C1512474
inhibitors	I:C1512474
since	O
they	O
will	O
induce	O
multidrug	O
resistance	O
in	O
cancer	B:C0334227
cells	I:C0334227
.	O

